The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Background Between people with and without inflammatory bowel disease (IBD), there was
no statistically significant difference in the probability of contracting the severe acute …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised
concerns in patients with inflammatory bowel disease (IBD), not only due to consequences …

Objectives: There is minimal evidence regarding the comparative effectiveness of individual
antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness …

(1) Scant information is available concerning the characteristics that may favour the
acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the …

Patients with inflammatory bowel disease (IBD) are vulnerable to vaccine-preventable
infectious diseases. Immunosuppressive drugs, which are often used to manage IBD, may …

Editors, We read with great intriguing the research TriNetX network analysis by Yousaf Hadi
et al. 1 They described a decreased risk of COVID-19 infection in the IBD patients with …

Patients with inflammatory bowel disease (IBD) may take medications that affect their
immune system, altering their ability to fight infection or making them less responsive to …

Editors, We read with interest the article by Hadi Y et al.“Incidence, outcomes, and impact of
COVID-19 on inflammatory bowel disease: propensity-matched research network analysis” …

Letter: the effect of anti‐COVID‐19 treatment on the outcome of patients with inflammatory
bowel disease Page 1 1462 | wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther …